HIV Hemophilia Ischemic heart disease
Conditions
Interventions
Eplerenone50mg once daily (initial 4 weeks), thereafter 50mg twice daily (total 100mg) for one year.Oral administration. Follow-up every 3 months.
Sponsors
Japan Institute for Health Security
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Patients who provided written consent to participate in the study 2) Males aged 20 years or older at the time of consent acquisition 3) Patients diagnosed with hemophilia 4) Patients with HIV infection 5) Patients with systolic blood pressure of 130 mmHg or higher, or who are taking antihypertensive medication
Exclusion criteria
Exclusion criteria: 1) Patients with a history of hypersensitivity to Eplerenone 2) Patients with elevated serum potassium levels(K>5.0mEq/L) 3) Patients with severe renal dysfunction(eGFR<30ml/min) 4) Patients with severe liver dysfunction(Child-Pugh Class C cirrhosis) 5) Patients with receiving potassium-sparing diuretics MRAs 6) Patients with receiving Itraconazole,Ritonavir-containing formulations,and ensitrelvir fumarate 7) Patients with receiving potassium supplements 8) Those who are judged by the principal investigator to be inappropriate for inclusion in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aortic and Background 18F-FDG uptake ratio (TBR) on FDG-PET before and after Eplerenone administration in hemophilia living with HIV | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory Markers (IL-6,TNFa, hs-CRP, sCD163, resistin, apelin) in hemophilia living with HIV before and after Eplerenone administration | — |
Countries
Japan
Contacts
Public ContactYukio Hiroi
Japan Institute for Health Security National Center for Global Health and Medicine Cardiology
Outcome results
None listed